ライフサイエンスコーパス: AED

1 AED coverage of cardiac arrests was defined as cardiac a

2 AED coverage of cardiac arrests was defined as historica

3 AED networks can be used as useful tools to optimize AED

4 AED reduction also predicted >/= 10-point IQ increase (p

5 AED selection requires consideration of many factors som

6 AED use statistically explained increased survival with

7 AEDs often produce adverse effects; treatment with immun

8 AEDs were used in 4515 patients (38.6%).

9 AEDs with low bioavailability and solubility (eg, oxcarb

10 ncrease for high-risk areas was from 1 to 30 AEDs and coverage from 5.7% to 51.3%, respectively.

11 included infants born to 6,777 AED-WWE, 696 AED-WWOE, and 486 no-AED-WWOE.

12 dy population included infants born to 6,777 AED-WWE, 696 AED-WWOE, and 486 no-AED-WWOE.

13 that occurred within 100 m of an accessible AED ("OHCA coverage") during the 2007 to 2016 period.

14 dens in children exposed prenatally to AEDs (AED-exposed children) versus children without BDs not ex

15 without BDs not exposed prenatally to AEDs (AED-unexposed unaffected children), and AED-exposed chil

16 ion to the location and accessibility of all AEDs linked to the emergency dispatch center as of Decem

17 needed to fully delineate the effects of all AEDs.

18 , there is controversy regarding whether all AEDs are substrates for this transporter.

19 Among AED-exposed children, there were no significant differen

20 stander, and 36% when a bystander applied an AED.

21 4) of all cardiac arrests were covered by an AED.

22 he drone network size required to deliver an AED 1, 2, or 3 minutes faster than historical median 911

23 d 100 drones would be required to deliver an AED ahead of median 911 response times by 3 minutes.

24 e an emerging technology that can deliver an AED to the scene of an out-of-hospital cardiac arrest fo

25 rrests (n=55) have occurred </=100 m from an AED with only 14.5% (n=8) being defibrillated before the

26 fined as historical arrests </=100 m from an AED.

27 ed before EMS arrival, and 289 (2.1%) had an AED applied before EMS arrival.

28 ardiac arrests within 100 m (109.4 yd) of an AED and further categorized according to AED accessibili

29 cy between drugs, FDA approval for use of an AED as monotherapy has typically been based on trials wi

30 Application of an AED in communities is associated with nearly a doubling

31 Placement of an AED in schools should be implemented with an emergency r

32 he first retrospective in silico trial of an AED placement intervention.

33 semination of on-site AEDs, foundation of an AED registry linked to emergency medical dispatch center

34 tegies, such as the ready availability of an AED, may be related to the place where the arrest occurs

35 uced in the AEx (-24.4%), diet (-23.2%), and AED (-47.9%) groups by contrast to the 20.9% increase in

36 not differ between AED-exposed children and AED-unexposed unaffected children (median dnSNV/indel nu

37 EDs (AED-unexposed unaffected children), and AED-exposed children with BDs versus those without BDs,

38 l rhythm (shockable versus nonshockable) and AED use.

39 ffer significantly between AED-unexposed and AED-exposed children.

40 , a predicted aspartyl protease, and another AED, LEGUME LECTIN-LIKE PROTEIN1 (LLP1), were induced lo

41 acy than currently available antiepileptics (AEDs).

42 By adapting APD-AED method in the case of UAE, the intensive optimum con

43 wer density and absorbed energy density (APD-AED) and response surface methodology (RSM).

44 001) for arrests in which bystanders applied AEDs.

45 e recommend that regulatory agencies approve AEDs for the treatment of specific seizure types or epil

46 In the systematic TDM arm, AED plasma levels were available at each appointment, wh

47 ually considers spatial AED access, assuming AEDs are available 24 h a day.

48 We investigated how volunteer-based AED dissemination affected public cardiac arrest coverag

49 he dnSNV/indel burden did not differ between AED-exposed children and AED-unexposed unaffected childr

50 /indels did not differ significantly between AED-unexposed and AED-exposed children.

51 suicide and the reported association between AEDs and risk of suicide.

52 Early reductions in both AED use and healthcare use were sustained long term.

53 The magnitude of this risk varies by AED exposure.

54 epileptic networks is effectively reduced by AEDs and suggest the proposed markers as useful candidat

55 istance from a cardiac arrest to the closest AED was 281 m.

56 ge), and the average distance to the closest AED would be 262 m.

57 age and decrease the distance to the closest AED.

58 drawal, number of AEDs reduced, and complete AED withdrawal were associated with improved postoperati

59 bination category based on their concomitant AED use.

60 Receipt of continued AED treatment (n = 23) or a standardized AMTR plus AED t

61 es during year 2 of follow-up than continued AED treatment alone.

62 Participants were randomized to continued AED treatment or AMTR 2003-2007, and observed for 2 year

63 Current AED coverage was quantified by determining the number of

64 lity at the time of cardiac arrest decreased AED coverage by 53.4% during the evening, nighttime, and

65 cess to an automated external defibrillator (AED) increases the chance of survival for out-of-hospita

66 0, and all automated external defibrillator (AED) locations registered with Toronto Emergency Medical

67 use of an automated external defibrillator (AED), for out-of-hospital arrests.

68 able by an automatic external defibrillator (AED), implantable cardioverter-defibrillator (ICD), or w

69 Automated external defibrillators (AEDs) are often placed in areas of low risk and limited

70 rest, but automated external defibrillators (AEDs) are rarely available for bystander use at the scen

71 nation of automated external defibrillators (AEDs) has been associated with more frequent AED use, th

72 Automated external defibrillators (AEDs) improve survival from out-of-hospital cardiac arre

73 n, use of automated external defibrillators (AEDs) in community settings is limited.

74 -deployed automated external defibrillators (AEDs) in public settings suggests that this may be the m

75 lation of automated external defibrillators (AEDs) in schools has been associated with increased surv

76 er use of automated external defibrillators (AEDs) to treat out-of-hospital cardiac arrest was advoca

77 in use of automated external defibrillators (AEDs), training first responders in team-based CPR inclu

78 nation of automated external defibrillators (AEDs).

79 s in patients with epilepsy should not delay AED treatment as the risks associated with seizures far

80 tification of 12 APOPLASTIC, EDS1-DEPENDENT (AED) proteins.

81 the trade-off between the number of deployed AEDs and coverage of cardiac arrests remains unclear.

82 ality via attrition-enhanced deracemization (AED) of enantiomorphic solids is carried out using molec

83 ion model was then developed that determined AED locations to maximize OHCA actual coverage and overc

84 ects of a hypocaloric, almond-enriched diet (AED) compared with a hypocaloric nut-free diet (NFD) on

85 29), diet (Diet n = 28), exercise plus diet (AED n = 29), or no-intervention (NI n = 29) groups.

86 , adults with concomitant use of 2 different AEDs and a recent partial-onset seizure diagnosis were s

87 case in a T-dependent allergic eye disease (AED) model, suggesting that this inflammatory neuroimmun

88 ed sediment cores of West Lake of El Dorado (AED), Calion Lake (ACL), and the lagoon of Magnolia Wast

89 is the first to describe antiepileptic drug (AED) combination therapy patterns according to their mec

90 Antiepileptic drug (AED) exposure during pregnancy increases the risk of maj

91 epilepsy with or without antiepileptic drug (AED) therapy and pregnancy and perinatal outcomes.

92 tfeeding during maternal antiepileptic drug (AED) therapy may be harmful.

93 soon after failure of 2 antiepileptic drug (AED) trials is superior to continued medical management

94 To investigate antiepileptic drug (AED)-related weight changes in patients with epilepsy th

95 generic formulations of antiepilepsy drugs (AEDs) may cause clinically significant changes in plasma

96 Antiepileptic drugs (AEDs) are commonly prescribed for epilepsy and bipolar d

97 epsy patients receiving antiepileptic drugs (AEDs) are not fully controlled by therapy.

98 Antiepileptic drugs (AEDs) are the only neurotherapeutics for which regulator

99 The mechanisms by which antiepileptic drugs (AEDs) cause birth defects (BDs) are unknown.

100 Currently available antiepileptic drugs (AEDs) fail to control seizures in 30% of patients.

101 Antiepileptic drugs (AEDs) have cognitive side effects that, particularly in

102 ) method to quantify 14 antiepileptic drugs (AEDs) in human serum.

103 olling its degree using antiepileptic drugs (AEDs) is of prime importance for clinical care and treat

104 rug monitoring (TDM) of antiepileptic drugs (AEDs) is widely established for older generation AEDs, w

105 Antiepileptic drugs (AEDs) remain the primary treatment.

106 fragments of well-known antiepileptic drugs (AEDs) such as ethosuximide, levetiracetam, and lacosamid

107 y used older generation antiepileptic drugs (AEDs) suggest that they might be responsible for a numbe

108 effects of epilepsy and antiepileptic drugs (AEDs) used during pregnancy on fetal growth and preterm

109 Antiepileptic drugs (AEDs) were generally ineffective and in 41% were associa

110 design and discovery of antiepileptic drugs (AEDs) with fewer side effects by focusing on astroglial

111 r's disease with select antiepileptic drugs (AEDs), in low doses, is usually well tolerated and effic

112 vailability of many new antiepileptic drugs (AEDs), only around 50% of people with epilepsy will beco

113 ilepsy are resistant to antiepileptic drugs (AEDs).

114 concile the effects of anti-epileptic drugs (AEDs) on individual neurons with their network-level act

115 g ingestion of typical anti-epileptic drugs (AEDs;).

116 n body weight after and before starting each AED (together with 95% CI and p values for no difference

117 l bias is compared for this near-equilibrium AED process and the far-from-equilibrium Soai autocataly

118 Multivariate analyses evaluated AED discontinuation risk and health care use according t

119 nd continuous efforts to introduce or extend AED programs.

120 eptic focus with a role of P-gp in extruding AEDs from the brain.

121 ubstitute rather than combine when the first AED produces an idiosyncratic reaction, is poorly tolera

122 3 and 12 months after starting, one of five AEDs.

123 udy was to develop an optimization model for AED deployment, accounting for spatial and temporal acce

124 mension of structural information needed for AED analysis.

125 The evidence for AEDs increasing risk for suicide remains mixed and is ba

126 AEDs) has been associated with more frequent AED use, the trade-off between the number of deployed AE

127 unclear why carbamazepine (CBZ), a frontline AED with a known molecular mechanism, has been reported

128 chromatography-atomic emission detector (GC-AED) was performed using the 181 nm sulfur canal.

129 Nonetheless, first-generation AEDs are still widely used.

130 Many new-generation AEDs have not been approved for monotherapy, causing dru

131 ic drug level monitoring of newer generation AEDs does not bring tangible benefits in the management

132 ssess the benefit of TDM of newer generation AEDs in epilepsy.

133 psy, in whom treatment with newer generation AEDs was initiated or needed adjustment.

134 Older generation AEDs are associated with a panoply of metabolic abnormal

135 ) is widely established for older generation AEDs, whereas there is limited evidence about newer AEDs

136 ed benefit; and (3) switches between generic AED formulations are safe and effective.

137 Switches between generic AED products may cause greater changes in plasma drug co

138 Most generic AED products provide total drug delivery (AUC) similar t

139 ulated switches between 595 pairs of generic AED formulations, estimated AUC(0-t) differed by >15% fo

140 Drug Administration claims that: (1) generic AEDs are accurate copies of reference formulations; (2)

141 quivalence (BE) studies for approved generic AEDs to evaluate US Food and Drug Administration claims

142 e formulations may be as variable as generic AEDs and so provide no increased benefit; and (3) switch

143 We assessed how AED accessibility affected coverage of cardiac arrests i

144 However, AED use during pregnancy is generally not associated wit

145 Mathematical optimization can improve AED accessibility but has not been compared with current

146 istics of modern AEDs, strategies to improve AED access and increase survival, ancillary treatments,

147 were found in all three water bodies (<1% in AED and ACL; and 1.1% and 4.1% in AMW, respectively).

148 thod was also used to increase confidence in AED identification using accurate mass and collision cro

149 ominant PBDE input (>99% in mole fraction in AED and ACL, and 94.7% in AMW).

150 Secular trends in AED prescribing during pregnancy were examined between 1

151 We examined secular trends in AED prescribing in pregnancy and pregnancy as a determin

152 One in 5 OHCAs occurred near an inaccessible AED at the time of the OHCA.

153 first responders in team-based CPR including AED use and high-performance CPR, and training dispatch

154 Increased AED use is associated with increased survival in patient

155 the current research evidence for increased AED-related suicide risk.

156 ints with epilepsy patients, mostly inducing AED treated, are consistent and concerning, however.

157 Limited AED accessibility at the time of cardiac arrest decrease

158 Limited AED accessibility decreased coverage of cardiac arrests

159 11.0%) remained on antiepileptic medication (AED).

160 lation of the U.S. and Canada (330 million), AED application by bystanders seems to save 474 lives/ye

161 ion, i.e. 70% EtOH, 30mL/g, APD of 0.22W/mL, AED of 450J/mL are able to achieve similar scale up resu

162 tained at 80% EtOH, 50mL/g, APD of 0.35W/mL, AED of 250J/mL can be used to determine the optimum cond

163 llation, technical characteristics of modern AEDs, strategies to improve AED access and increase surv

164 Moreover, AEDs have many physiologic and pharmacologic effects tha

165 Multiplexed AED measurements using LC-MS/MS and LC-DTIM-MS have the

166 rs following adequate trials of 2 brand-name AEDs.

167 vings in the time and cost of developing new AEDs.

168 Newer AEDs, many with different mechanisms of action, have inc

169 hereas there is limited evidence about newer AEDs.

170 der cardiopulmonary resuscitation but had no AED applied before EMS arrival, and 289 (2.1%) had an AE

171 n to 6,777 AED-WWE, 696 AED-WWOE, and 486 no-AED-WWOE.

172 10 and 136g, respectively, as compared to no-AED-WWOE.

173 rence of clinicians to TDM (adjusting or not AED dosage based on blood levels) did not explain this l

174 FINDINGS: Prior to the introduction of novel AEDs, it was generally opined that combining traditional

175 trong determinant for the discontinuation of AED prescribing particularly for women with bipolar diso

176 alyses to compare time to discontinuation of AED prescriptions between pregnant and non-pregnant wome

177 The distribution of AED location was consistently skewed in favor of public

178 We now aimed to evaluate the effect of AED withdrawal on postoperative intelligence quotient (I

179 No adverse effects of AED exposure via breast milk were observed at age 6 year

180 y of long-term neurodevelopmental effects of AED use.

181 aid in the separation and identification of AED structural isomers and other AEDs.

182 a significant covariation with the level of AED load and a wake-dependent modulation.

183 and in the associated research promotions of AED.

184 Rates of AED use almost tripled during the study period (21.4% to

185 Regardless of AED accessibility, 28.8% (537 of 1864) of all cardiac ar

186 t persistence was measured from the start of AED combination therapy until the end of the combination

187 Start of AED withdrawal, number of AEDs reduced, and complete AED

188 ToStop (TTS) study, we showed that timing of AED withdrawal does not majorly influence long-term seiz

189 viously identified determinants of timing of AED withdrawal.

190 quate measures of excitability and action of AEDs have been difficult to identify.

191 eizure is rescued by prior administration of AEDs, opening a new perspective for early drug intervent

192 er's disease suggest that certain classes of AEDs that reduce network hyperexcitability have disease-

193 Because head-to-head comparisons of AEDs (used in the European Union to approve drugs for mo

194 y identify neuropsychiatric complications of AEDs.

195 to identify predictors of discontinuation of AEDs in pregnancy.

196 From 2007 to 2011, the number of AEDs and the corresponding coverage of cardiac arrests i

197 access defibrillation program, the number of AEDs increased 15-fold with a corresponding increase in

198 Start of AED withdrawal, number of AEDs reduced, and complete AED withdrawal were associate

199 The higher the number of AEDs reduced, the higher was the IQ (gain) after surgery

200 07) were used to optimize an equal number of AEDs to the control group in locations with availabiliti

201 Reduction of AEDs at the latest NPA significantly improved postoperat

202 ; n = 301) and analyzed whether reduction of AEDs prior to the latest NPA was related to postoperativ

203 perinatal outcomes as well as whether use of AEDs influenced risks.

204 talized patients with cardiac arrest, use of AEDs was not associated with improved survival.

205 Within users of AEDs in monotherapy, the prevalence of SGA ranged from 7

206 Another older AED, valproate, is associated with the occurrence of pol

207 reasingly prescribed in pregnancy over older AEDs namely carbamazepine and sodium valproate.

208 Information on AED exposure was available in the subset of offspring fr

209 INTERPRETATION: Women on AEDs during pregnancy, whether for epilepsy or for other

210 However, only AED group significantly decreased HbA1c (-4.4%, p = 0.01

211 Using the spatiotemporal model to optimize AED deployment, a 25.3% relative increase in actual cove

212 orks can be used as useful tools to optimize AED placement in community settings.

213 Optimized AED deployment can increase cardiac arrest coverage and

214 Optimized AED placements increased OHCA coverage by approximately

215 compared with real AED locations, optimized AED locations improve coverage of out-of-hospital cardia

216 fication of AED structural isomers and other AEDs.

217 , 95% CI = 1.0-4.2, p = 0.001, IQ points per AED reduced).

218 eatment (n = 23) or a standardized AMTR plus AED treatment (n = 15).

219 table disabling MTLE, resective surgery plus AED treatment resulted in a lower probability of seizure

220 dily increased and has been the most popular AED prescribed in pregnancy since 2004.

221 Potential AED use was significantly improved with a spatiotemporal

222 g methodology for the discovery of potential AEDs.

223 Our study indicates that prenatal AED exposure does not increase the burden of de novo var

224 4 despite being the most commonly prescribed AEDs in pregnancy up to 2004.

225 Prospective AED trials should include validated scales to systematic

226 Mathematical modeling can augment public AED deployment programs.

227 nequivocal funding to schools for purchasing AEDs.

228 lic OHCAs of presumed cardiac cause and real AED deployed (control group) from 2007 to 2016 in Copenh

229 OHCA coverage of real AED placements was 22.0%.

230 erage by approximately 50% to 100% over real AED placements, leading to significant predicted increas

231 ght to determine whether, compared with real AED locations, optimized AED locations improve coverage

232 lepsy were twice as likely to stop receiving AEDs (Hazard Ratio (HR) 2.00, 95% Confidence Interval (C

233 pregnancy were more likely to stop receiving AEDs in pregnancy.

234 regnant women with epilepsy, those receiving AEDs less regularly before pregnancy were more likely to

235 4 were within 100 m of at least 1 registered AED (23% coverage).

236 nontraumatic public OHCAs and 737 registered AED locations were identified.

237 t occurred within 100 meters of a registered AED (assumed coverage 24 h per day, 7 days per week) wit

238 urred both within 100 meters of a registered AED and when the AED was available (actual coverage).

239 ters of cardiac arrests without a registered AED within 100 m were identified.

240 rests occurring within 100 m of a registered AED.

241 location cardiac arrests and 1669 registered AEDs.

242 Of 552 registered AEDs, 9.1% (n=50) were accessible at all hours, and 96.4

243 e were 673 public OHCAs and 1,573 registered AEDs from 2007 to 2016.

244 rdiac arrests (1994-2011) and all registered AEDs (2007-2011) in Copenhagen, Denmark, were identified

245 otal of 451 OHCAs were covered by registered AEDs under assumed coverage 24 h per day, 7 days per wee

246 gust 2014) and obtained a list of registered AEDs (March 2015) from Toronto Paramedic Services.

247 The number of registered AEDs increased from 141 in 2007 to 7800 in 2012.

248 tter safety profile than clinically relevant AEDs ethosuximide, lacosamide, or valproic acid.

249 ary 2016, 17 of 50 U.S. states (34%) require AED installation in at least some of their schools; the

250 ty of U.S. states have legislation requiring AED placement in schools, and even fewer provide funding

251 t have not yet enacted legislation requiring AEDs in schools may look to neighboring states for examp

252 cardiac arrests due to nonshockable rhythms, AED use was associated with lower survival (10.4% vs 15.

253 e bystander CPR and implementation of school AEDs and other public access defibrillation programs imp

254 the patient tolerates their first or second AED well, but with a suboptimal response, particularly w

255 es and 30.0% fewer drones to achieve similar AED delivery times.

256 of Danish citizens, dissemination of on-site AEDs, foundation of an AED registry linked to emergency

257 or not shockable rhythm; and 7) study site, AED application was associated with greater likelihood o

258 Current deployment usually considers spatial AED access, assuming AEDs are available 24 h a day.

259 and pregnancy as a determinant for stopping AED prescribing.

260 In these studies, AED linearity, analyte recovery, matrix effects, precisi

261 answers on whether to combine or substitute AEDs.

262 The findings suggest that AED combinations with different MOAs have greater effect

263 Data suggest that AED-induced BDs may result from a genome-wide increase o

264 An FDA alert in 2008 raised concerns that AEDs may increase the risk of suicidal thoughts and beha

265 The AED and NFD groups experienced clinically significant an

266 The AED, compared with the NFD, was associated with greater

267 Despite smaller weight loss in the AED group at 6 mo, the AED group experienced greater imp

268 Those in the AED group lost slightly but significantly less weight th

269 er weight loss in the AED group at 6 mo, the AED group experienced greater improvements in lipid prof

270 ost urban region, the 90th percentile of the AED arrival time was reduced by 6 minutes and 43 seconds

271 Since the establishment of the AED network (2007-2011), few arrests (n=55) have occurre

272 o maximize the impact of the presence of the AED.

273 hematical model can substantially reduce the AED delivery time to an out-of-hospital cardiac arrest e

274 ted the weight difference after starting the AED for each patient.

275 100 meters of a registered AED and when the AED was available (actual coverage).

276 These AEDs target mechanisms of epileptogenesis involving amyl

277 he apparent permeability (Papp) of the three AEDs in the absence or presence of P-gp inhibitors.

278 an AED and further categorized according to AED accessibility at the time of cardiac arrest.

279 and, if so, whether this is attributable to AED use.

280 this mechanism is not a major contributor to AED-induced BDs.

281 imization and queuing can reduce the time to AED arrival.

282 As an alternative to AEDs, novel therapies based on cell transplantation offe

283 Prenatal exposure to AEDs in WWE and WWOE was associated with a mean lower bi

284 ify all current state statutes pertaining to AEDs in schools.

285 nt burdens in children exposed prenatally to AEDs (AED-exposed children) versus children without BDs

286 ildren without BDs not exposed prenatally to AEDs (AED-unexposed unaffected children), and AED-expose

287 us (SGA) among infants exposed prenatally to AEDs when used by women with epilepsy (WWE) or women wit

288 ompared with that among infants unexposed to AEDs and born to WWOE.

289 y strategic placement but also uninterrupted AED accessibility warrant attention if public-access def

290 In women with epilepsy, using AEDs during pregnancy did not increase the risks of preg

291 itored and nonmonitored hospital units where AEDs were used, after matching patients to the individua

292 d by EMS personnel or bystanders and whether AEDs are applied by bystanders, the proportion of arrest

293 th Alzheimer's disease will identify whether AEDs or related strategies could improve their cognitive

294 tment options and issues influencing whether AEDs should be substituted or combined in the remainder

295 en child-parent trios were included: 10 with AED-exposed children with BDs, 46 with AED-exposed unaff

296 AED-exposed unaffected children, and 11 with AED-unexposed unaffected children.

297 with AED-exposed children with BDs, 46 with AED-exposed unaffected children, and 11 with AED-unexpos

298 The dnCNV burden was not associated with AED exposure or birth outcome.

299 rse effects of breastfeeding associated with AED use on IQ at age 3 years, but IQ at age 6 years is m

300 With AEDs deployed in the top 30 locations, an additional 112

301 was 34% for arrests in public settings with AEDs applied by bystanders versus 12% for arrests at hom